Form 4: Fennec Pharmaceuticals CFO Reports Share Release
SEC Form 4 Filing
Robert Andrade, CFO of Fennec Pharmaceuticals, reports the release of 1,042 common shares from restriction on September 30, 2024.
Summary
- Robert Andrade, the Chief Financial Officer of Fennec Pharmaceuticals, reported a transaction on September 30, 2024.
- 1,042 common shares were released from restriction and acquired by Andrade at a price of $0.
- Following this transaction, Andrade beneficially owns 110,523 common shares.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral.
Positives
- The release of restricted shares to a key executive could be seen as a positive sign of alignment with company goals.
Industry Context
Form 4 filings are a routine part of compliance for publicly traded companies, providing transparency into the transactions of company insiders.
Stakeholder Impact
- The transaction could have a minor impact on shareholders by slightly increasing the number of outstanding shares.
Key Dates
| Date | Description |
|---|---|
| 03/31/2023 | Date of original share award. |
| 09/30/2024 | Date of transaction: Release of restricted shares. |
| 10/01/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.